{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:26:42Z","timestamp":1790519202942,"version":"4.1.0"},"reference-count":161,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T00:00:00Z","timestamp":1539129600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1038\/s41584-018-0099-0","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T12:27:43Z","timestamp":1539174463000},"page":"657-673","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["New insights into the genetics and epigenetics of systemic sclerosis"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1404-4429","authenticated-orcid":false,"given":"Chiara","family":"Angiolilli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wioleta","family":"Marut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"van der Kroef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Chouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris A.","family":"Reedquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R. D. J.","family":"Radstake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,10]]},"reference":[{"key":"99_CR1","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","volume":"360","author":"A Gabrielli","year":"2009","unstructured":"Gabrielli, A., Avvedimento, E. V. & Krieg, T. Scleroderma. N. Engl. J. Med. 360, 1989\u20132003 (2009).","journal-title":"N. Engl. J. Med."},{"key":"99_CR2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"[No authors listed]","year":"1980","unstructured":"[No authors listed]. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 23, 581\u2013590 (1980).","journal-title":"Arthritis Rheum."},{"key":"99_CR3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/BOR.0b013e32834ff2e8","volume":"24","author":"J Barnes","year":"2012","unstructured":"Barnes, J. & Mayes, M. D. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr. Opin. Rheumatol. 24, 165\u2013170 (2012).","journal-title":"Curr. Opin. Rheumatol."},{"key":"99_CR4","first-page":"1573","volume":"28","author":"EC LeRoy","year":"2001","unstructured":"LeRoy, E. C. & Medsger, T. A. Jr. Criteria for the classification of early systemic sclerosis. J. Rheumatol. 28, 1573\u20131576 (2001).","journal-title":"J. Rheumatol."},{"key":"99_CR5","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F Hoogen van den","year":"2013","unstructured":"van den Hoogen, F. et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann. Rheum. Dis. 72, 1747\u20131755 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"99_CR6","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.rdc.2015.04.003","volume":"41","author":"JE Pope","year":"2015","unstructured":"Pope, J. E. & Johnson, S. R. New classification criteria for systemic sclerosis (scleroderma). Rheum. Dis. Clin. North Am. 41, 383\u2013398 (2015).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"99_CR7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.semarthrit.2007.05.003","volume":"37","author":"H Chifflot","year":"2008","unstructured":"Chifflot, H., Fautrel, B., Sordet, C., Chatelus, E. & Sibilia, J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin. Arthritis Rheum. 37, 223\u2013235 (2008).","journal-title":"Semin. Arthritis Rheum."},{"key":"99_CR8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1046\/j.1445-5994.2001.00048.x","volume":"31","author":"PJ Roberts-Thomson","year":"2001","unstructured":"Roberts-Thomson, P. J. et al. Scleroderma in South Australia: epidemiological observations of possible pathogenic significance. Intern. Med. J. 31, 220\u2013229 (2001).","journal-title":"Intern. Med. J."},{"key":"99_CR9","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/art.11073","volume":"48","author":"MD Mayes","year":"2003","unstructured":"Mayes, M. D. et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 48, 2246\u20132255 (2003).","journal-title":"Arthritis Rheum."},{"key":"99_CR10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1586\/1744666X.2016.1125782","volume":"12","author":"M Martinis De","year":"2016","unstructured":"De Martinis, M., Ciccarelli, F., Sirufo, M. M. & Ginaldi, L. An overview of environmental risk factors in systemic sclerosis. Expert Rev. Clin. Immunol. 12, 465\u2013478 (2016).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"99_CR11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00420-009-0505-7","volume":"83","author":"ZD McCormic","year":"2010","unstructured":"McCormic, Z. D., Khuder, S. S., Aryal, B. K., Ames, A. L. & Khuder, S. A. Occupational silica exposure as a risk factor for scleroderma: a meta-analysis. Int. Arch. Occup. Environ. Health 83, 763\u2013769 (2010).","journal-title":"Int. Arch. Occup. Environ. Health"},{"key":"99_CR12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/sji.12595","volume":"86","author":"M Walczyk","year":"2017","unstructured":"Walczyk, M., Paradowska-Gorycka, A. & Olesinska, M. Epigenetics: the future direction in systemic sclerosis. Scand. J. Immunol. 86, 427\u2013435 (2017).","journal-title":"Scand. J. Immunol."},{"key":"99_CR13","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrrheum.2014.128","volume":"10","author":"JC Broen","year":"2014","unstructured":"Broen, J. C., Radstake, T. R. & Rossato, M. The role of genetics and epigenetics in the pathogenesis of systemic sclerosis. Nat. Rev. Rheumatol. 10, 671\u2013681 (2014).","journal-title":"Nat. Rev. Rheumatol."},{"key":"99_CR14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1445-5994.1999.tb01586.x","volume":"29","author":"H Englert","year":"1999","unstructured":"Englert, H. et al. Familial risk estimation in systemic sclerosis. Aust. N. Z. J. Med. 29, 36\u201341 (1999).","journal-title":"Aust. N. Z. J. Med."},{"key":"99_CR15","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/1529-0131(200106)44:6<1359::AID-ART228>3.0.CO;2-S","volume":"44","author":"FC Arnett","year":"2001","unstructured":"Arnett, F. C. et al. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum. 44, 1359\u20131362 (2001).","journal-title":"Arthritis Rheum."},{"key":"99_CR16","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/art.11173","volume":"48","author":"C Feghali-Bostwick","year":"2003","unstructured":"Feghali-Bostwick, C., Medsger, T. A. Jr & Wright, T. M. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum. 48, 1956\u20131963 (2003).","journal-title":"Arthritis Rheum."},{"key":"99_CR17","first-page":"899","volume":"13","author":"K Aho","year":"1986","unstructured":"Aho, K., Koskenvuo, M., Tuominen, J. & Kaprio, J. Occurrence of rheumatoid arthritis in a nationwide series of twins. J. Rheumatol. 13, 899\u2013902 (1986).","journal-title":"J. Rheumatol."},{"key":"99_CR18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/BF00242661","volume":"181","author":"H Bammer","year":"1960","unstructured":"Bammer, H., Schaltenbrand, G. & Solcher, H. [Examinations of twins in multiple sclerosis]. Dtsch. Z. Nervenheilkd 181, 261\u2013279 (1960).","journal-title":"Dtsch. Z. Nervenheilkd"},{"key":"99_CR19","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.gastro.2004.05.005","volume":"127","author":"C Selmi","year":"2004","unstructured":"Selmi, C. et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology 127, 485\u2013492 (2004).","journal-title":"Gastroenterology"},{"key":"99_CR20","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1002\/art.21355","volume":"52","author":"X Zhou","year":"2005","unstructured":"Zhou, X., Tan, F. K., Xiong, M., Arnett, F. C. & Feghali-Bostwick, C. A. Monozygotic twins clinically discordant for scleroderma show concordance for fibroblast gene expression profiles. Arthritis Rheum. 52, 3305\u20133314 (2005).","journal-title":"Arthritis Rheum."},{"key":"99_CR21","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaut.2008.05.002","volume":"31","author":"M Hudson","year":"2008","unstructured":"Hudson, M. et al. Polyautoimmunity and familial autoimmunity in systemic sclerosis. J. Autoimmun. 31, 156\u2013159 (2008).","journal-title":"J. Autoimmun."},{"key":"99_CR22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jaut.2010.02.001","volume":"35","author":"RK Arora-Singh","year":"2010","unstructured":"Arora-Singh, R. K. et al. Autoimmune diseases and autoantibodies in the first degree relatives of patients with systemic sclerosis. J. Autoimmun. 35, 52\u201357 (2010).","journal-title":"J. Autoimmun."},{"key":"99_CR23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.humimm.2016.10.017","volume":"78","author":"P Chairta","year":"2017","unstructured":"Chairta, P., Nicolaou, P. & Christodoulou, K. Genomic and genetic studies of systemic sclerosis: a systematic review. Hum. Immunol. 78, 153\u2013165 (2017).","journal-title":"Hum. Immunol."},{"key":"99_CR24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ajhg.2013.12.002","volume":"94","author":"MD Mayes","year":"2014","unstructured":"Mayes, M. D. et al. Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. Am. J. Hum. Genet. 94, 47\u201361 (2014).","journal-title":"Am. J. Hum. Genet."},{"key":"99_CR25","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1136\/ard.2009.111906","volume":"69","author":"FC Arnett","year":"2010","unstructured":"Arnett, F. C. et al. Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann. Rheum. Dis. 69, 822\u2013827 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"99_CR26","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/rheumatology\/ker335","volume":"51","author":"L Beretta","year":"2012","unstructured":"Beretta, L. et al. Analysis of class II human leucocyte antigens in Italian and Spanish systemic sclerosis. Rheumatol. 51, 52\u201359 (2012).","journal-title":"Rheumatol."},{"key":"99_CR27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126727","volume":"10","author":"TS Rodriguez-Reyna","year":"2015","unstructured":"Rodriguez-Reyna, T. S. et al. HLA class I and II blocks are associated to susceptibility, clinical subtypes and autoantibodies in Mexican systemic sclerosis (SSc) patients. PLoS ONE 10, e0126727 (2015).","journal-title":"PLoS ONE"},{"key":"99_CR28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154255","volume":"11","author":"H Furukawa","year":"2016","unstructured":"Furukawa, H. et al. Human leukocyte antigen and systemic sclerosis in Japanese: the sign of the four independent protective alleles, DRB1*13:02, DRB1*14:06, DQB1*03:01, and DPB1*02:01. PLoS ONE 11, e0154255 (2016).","journal-title":"PLoS ONE"},{"key":"99_CR29","volume":"9","author":"J Wang","year":"2014","unstructured":"Wang, J. et al. Association of HLA-DPB1 with scleroderma and its clinical features in Chinese population. PLoS ONE 9, e87363 (2014).","journal-title":"PLoS ONE"},{"key":"99_CR30","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/rheumatology\/keu381","volume":"54","author":"B Vigone","year":"2015","unstructured":"Vigone, B. et al. Role of class II human leucocyte antigens in the progression from early to definite systemic sclerosis. Rheumatol. 54, 707\u2013711 (2015).","journal-title":"Rheumatol."},{"key":"99_CR31","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/1529-0131(200009)43:9<2005::AID-ANR11>3.0.CO;2-#","volume":"43","author":"NC Lambert","year":"2000","unstructured":"Lambert, N. C. et al. HLA-DQA1*0501 is associated with diffuse systemic sclerosis in Caucasian men. Arthritis Rheum. 43, 2005\u20132010 (2000).","journal-title":"Arthritis Rheum."},{"key":"99_CR32","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1002\/art.39765","volume":"68","author":"AM Stevens","year":"2016","unstructured":"Stevens, A. M. et al. Brief report: HLA-DRB1, DQA1, and DQB1 in juvenile-onset systemic sclerosis. Arthritis Rheumatol. 68, 2772\u20132777 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"99_CR33","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/ard.2011.150326","volume":"70","author":"BW Higgs","year":"2011","unstructured":"Higgs, B. W. et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann. Rheum. Dis. 70, 2029\u20132036 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"99_CR34","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/ijd.12839","volume":"55","author":"Y Xu","year":"2016","unstructured":"Xu, Y., Wang, W., Tian, Y., Liu, J. & Yang, R. Polymorphisms in STAT4 and IRF5 increase the risk of systemic sclerosis: a meta-analysis. Int. J. Dermatol. 55, 408\u2013416 (2016).","journal-title":"Int. J. Dermatol."},{"key":"99_CR35","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/art.39730","volume":"68","author":"E Lopez-Isac","year":"2016","unstructured":"Lopez-Isac, E. et al. Brief report: IRF4 newly identified as a common susceptibility locus for systemic sclerosis and rheumatoid arthritis in a cross-disease meta-analysis of genome-wide association studies. Arthritis Rheumatol. 68, 2338\u20132344 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"99_CR36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002091","volume":"7","author":"Y Allanore","year":"2011","unstructured":"Allanore, Y. et al. Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet. 7, e1002091 (2011).","journal-title":"PLoS Genet."},{"key":"99_CR37","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1093\/hmg\/dds099","volume":"21","author":"JE Martin","year":"2012","unstructured":"Martin, J. E. et al. Identification of CSK as a systemic sclerosis genetic risk factor through genome wide association study follow-up. Hum. Mol. Genet. 21, 2825\u20132835 (2012).","journal-title":"Hum. Mol. Genet."},{"key":"99_CR38","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/ng.565","volume":"42","author":"TR Radstake","year":"2010","unstructured":"Radstake, T. R. et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat. Genet. 42, 426\u2013429 (2010).","journal-title":"Nat. Genet."},{"key":"99_CR39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2174\/1874312901408010043","volume":"8","author":"J Wang","year":"2014","unstructured":"Wang, J. et al. Lack of association of the CD247 SNP rs2056626 with systemic sclerosis in Han Chinese. Open Rheumatol. J. 8, 43\u201345 (2014).","journal-title":"Open Rheumatol. J."},{"key":"99_CR40","first-page":"2838","volume":"27","author":"S Sato","year":"2000","unstructured":"Sato, S. et al. Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis. J. Rheumatol. 27, 2838\u20132842 (2000).","journal-title":"J. Rheumatol."},{"key":"99_CR41","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/hmg\/ddr522","volume":"21","author":"L Bossini-Castillo","year":"2012","unstructured":"Bossini-Castillo, L. et al. A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Hum. Mol. Genet. 21, 926\u2013933 (2012).","journal-title":"Hum. Mol. Genet."},{"key":"99_CR42","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1002\/art.38870","volume":"66","author":"E Lopez-Isac","year":"2014","unstructured":"Lopez-Isac, E. et al. Identification of IL12RB1 as a novel systemic sclerosis susceptibility locus. Arthritis Rheumatol. 66, 3521\u20133523 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"99_CR43","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1093\/hmg\/ddt248","volume":"22","author":"JE Martin","year":"2013","unstructured":"Martin, J. E. et al. A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. Hum. Mol. Genet. 22, 4021\u20134029 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"99_CR44","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/ard.2009.111310","volume":"68","author":"N Tsuchiya","year":"2009","unstructured":"Tsuchiya, N. et al. Association of STAT4 polymorphism with systemic sclerosis in a Japanese population. Ann. Rheum. Dis. 68, 1375\u20131376 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"99_CR45","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.imbio.2015.04.003","volume":"220","author":"R Elshazli","year":"2015","unstructured":"Elshazli, R. & Settin, A. Association of PTPN22 rs2476601 and STAT4 rs7574865 polymorphisms with rheumatoid arthritis: a meta-analysis update. Immunobiology 220, 1012\u20131024 (2015).","journal-title":"Immunobiology"},{"key":"99_CR46","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/gene.2010.29","volume":"11","author":"N Gestermann","year":"2010","unstructured":"Gestermann, N. et al. STAT4 is a confirmed genetic risk factor for Sj\u00f6gren\u2019s syndrome and could be involved in type 1 interferon pathway signaling. Genes Immun. 11, 432\u2013438 (2010).","journal-title":"Genes Immun."},{"key":"99_CR47","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/art.24387","volume":"60","author":"B Namjou","year":"2009","unstructured":"Namjou, B. et al. High-density genotyping of STAT4 reveals multiple haplotypic associations with systemic lupus erythematosus in different racial groups. Arthritis Rheum. 60, 1085\u20131095 (2009).","journal-title":"Arthritis Rheum."},{"key":"99_CR48","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2177\/jsci.33.57","volume":"33","author":"N Tsuchiya","year":"2010","unstructured":"Tsuchiya, N., Ito, I. & Kawasaki, A. Association of IRF5, STAT4 and BLK with systemic lupus erythematosus and other rheumatic diseases. Nihon Rinsho Meneki Gakkai Kaishi 33, 57\u201365 (2010).","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"99_CR49","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/art.24600","volume":"60","author":"I Ito","year":"2009","unstructured":"Ito, I. et al. Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population. Arthritis Rheum. 60, 1845\u20131850 (2009).","journal-title":"Arthritis Rheum."},{"issue":"Suppl. 100","key":"99_CR50","first-page":"43","volume":"34","author":"E Koumakis","year":"2016","unstructured":"Koumakis, E. et al. A candidate gene study identifies a haplotype of CD2 as novel susceptibility factor for systemic sclerosis. Clin. Exp. Rheumatol. 34 (Suppl. 100), 43\u201348 (2016).","journal-title":"Clin. Exp. Rheumatol."},{"key":"99_CR51","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cell.2016.05.034","volume":"166","author":"V Sisirak","year":"2016","unstructured":"Sisirak, V. et al. Digestion of chromatin in apoptotic cell microparticles prevents autoimmunity. Cell 166, 88\u2013101 (2016).","journal-title":"Cell"},{"key":"99_CR52","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/s13075-014-0438-8","volume":"16","author":"J Zochling","year":"2014","unstructured":"Zochling, J. et al. An Immunochip-based interrogation of scleroderma susceptibility variants identifies a novel association at DNASE1L3. Arthritis Res. Ther. 16, 438 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"99_CR53","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/art.39476","volume":"68","author":"P Wei","year":"2016","unstructured":"Wei, P. et al. Identification of an association of TNFAIP3 polymorphisms with matrix metalloproteinase expression in fibroblasts in an integrative study of systemic sclerosis-associated genetic and environmental factors. Arthritis Rheumatol. 68, 749\u2013760 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"99_CR54","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/RHU.0000000000000354","volume":"22","author":"JH Zhao","year":"2016","unstructured":"Zhao, J. H. et al. The influence of different solvents on systemic sclerosis: an updated meta-analysis of 14 case-control studies. J. Clin. Rheumatol. 22, 253\u2013259 (2016).","journal-title":"J. Clin. Rheumatol."},{"key":"99_CR55","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.autrev.2014.10.021","volume":"14","author":"AS Johar","year":"2015","unstructured":"Johar, A. S. et al. Candidate gene discovery in autoimmunity by using extreme phenotypes, next generation sequencing and whole exome capture. Autoimmun Rev. 14, 204\u2013209 (2015).","journal-title":"Autoimmun Rev."},{"key":"99_CR56","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/art.39449","volume":"68","author":"L Gao","year":"2016","unstructured":"Gao, L. et al. Identification of rare variants in ATP8B4 as a risk factor for systemic sclerosis by whole-exome sequencing. Arthritis Rheumatol. 68, 191\u2013200 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"99_CR57","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/art.40058","volume":"69","author":"E Lopez-Isac","year":"2017","unstructured":"Lopez-Isac, E. et al. Analysis of ATP8B4 F436L missense variant in a large systemic sclerosis cohort. Arthritis Rheumatol. 69, 1337\u20131338 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"99_CR58","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1002\/art.39721","volume":"68","author":"AC Mak","year":"2016","unstructured":"Mak, A. C. et al. Brief report: whole-exome sequencing for identification of potential causal variants for diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 68, 2257\u20132262 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"99_CR59","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1002\/art.24885","volume":"60","author":"P Dieude","year":"2009","unstructured":"Dieude, P. et al. BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4. Arthritis Rheum. 60, 3447\u20133454 (2009).","journal-title":"Arthritis Rheum."},{"key":"99_CR60","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","volume":"370","author":"L Bon van","year":"2014","unstructured":"van Bon, L. et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N. Engl. J. Med. 370, 433\u2013443 (2014).","journal-title":"N. Engl. J. Med."},{"key":"99_CR61","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/ard.2009.128207","volume":"69","author":"L Bon van","year":"2010","unstructured":"van Bon, L. et al. Distinct evolution of TLR-mediated dendritic cell cytokine secretion in patients with limited and diffuse cutaneous systemic sclerosis. Ann. Rheum. Dis. 69, 1539\u20131547 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"99_CR62","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam8458","volume":"10","author":"MD Ah Kioon","year":"2018","unstructured":"Ah Kioon, M. D. et al. Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8. Sci. Transl Med. 10, eaam8458 (2018).","journal-title":"Sci. Transl Med."},{"key":"99_CR63","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4049\/jimmunol.1602020","volume":"199","author":"SC Silva-Cardoso","year":"2017","unstructured":"Silva-Cardoso, S. C. et al. CXCL4 exposure potentiates TLR-driven polarization of human monocyte-derived dendritic cells and increases stimulation of T cells. J. Immunol. 199, 253\u2013262 (2017).","journal-title":"J. Immunol."},{"key":"99_CR64","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/annrheumdis-2014-205303","volume":"74","author":"N Altorok","year":"2015","unstructured":"Altorok, N., Tsou, P. S., Coit, P., Khanna, D. & Sawalha, A. H. Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies. Ann. Rheum. Dis. 74, 1612\u20131620 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"99_CR65","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/exd.12767","volume":"24","author":"M Hattori","year":"2015","unstructured":"Hattori, M. et al. Global DNA hypomethylation and hypoxia-induced expression of the ten eleven translocation (TET) family, TET1, in scleroderma fibroblasts. Exp. Dermatol. 24, 841\u2013846 (2015).","journal-title":"Exp. Dermatol."},{"key":"99_CR66","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/jid.2009.318","volume":"130","author":"JL Sargent","year":"2010","unstructured":"Sargent, J. L. et al. A TGF\u03b2-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J. Invest. Dermatol. 130, 694\u2013705 (2010).","journal-title":"J. Invest. Dermatol."},{"key":"99_CR67","doi-asserted-by":"crossref","first-page":"6064830","DOI":"10.1155\/2016\/6064830","volume":"2016","author":"AT Dantas","year":"2016","unstructured":"Dantas, A. T. et al. Reassessing the role of the active TGF-\u03b21 as a biomarker in systemic sclerosis: association of serum levels with clinical manifestations. Dis. Markers 2016, 6064830 (2016).","journal-title":"Dis. Markers"},{"key":"99_CR68","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/annrheumdis-2012-203194","volume":"73","author":"C Dees","year":"2014","unstructured":"Dees, C. et al. The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Ann. Rheum. Dis. 73, 1232\u20131239 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"99_CR69","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms6797","volume":"5","author":"S Noda","year":"2014","unstructured":"Noda, S. et al. Simultaneous downregulation of KLF5 and FLI1 is a key feature underlying systemic sclerosis. Nat. Commun. 5, 5797 (2014).","journal-title":"Nat. Commun."},{"key":"99_CR70","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/annrheumdis-2017-212265","volume":"77","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis. Ann. Rheum. Dis. 77, 744\u2013751 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"99_CR71","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.3892\/ijmm.2012.1150","volume":"30","author":"AM Bujor","year":"2012","unstructured":"Bujor, A. M. et al. Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of DNMT1 and upregulation of FLI1. Int. J. Mol. Med. 30, 1473\u20131480 (2012).","journal-title":"Int. J. Mol. Med."},{"key":"99_CR72","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/03009740902758875","volume":"38","author":"W Lei","year":"2009","unstructured":"Lei, W. et al. Abnormal DNA methylation in CD4+ T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis. Scand. J. Rheumatol. 38, 369\u2013374 (2009).","journal-title":"Scand. J. Rheumatol."},{"key":"99_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/bies.201700010","author":"Y Qing","year":"2017","unstructured":"Qing, Y. et al. Quantitation and mapping of the epigenetic marker 5-hydroxymethylcytosine. Bioessays https:\/\/doi.org\/10.1002\/bies.201700010 (2017).","journal-title":"Bioessays"},{"key":"99_CR74","doi-asserted-by":"crossref","first-page":"E633","DOI":"10.3390\/ijms18030633","volume":"18","author":"S Zhang","year":"2017","unstructured":"Zhang, S. et al. miR-30a as potential therapeutics by targeting TET1 through regulation of Drp-1 promoter hydroxymethylation in idiopathic pulmonary fibrosis. Int. J. Mol. Sci. 18, E633 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"99_CR75","volume":"6","author":"S O\u2019Reilly","year":"2016","unstructured":"O\u2019Reilly, S., Ciechomska, M., Fullard, N., Przyborski, S. & van Laar, J. M. IL-13 mediates collagen deposition via STAT6 and microRNA-135b: a role for epigenetics. Sci. Rep. 6, 25066 (2016).","journal-title":"Sci. Rep."},{"key":"99_CR76","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1136\/annrheumdis-2018-213022","volume":"77","author":"Y He","year":"2018","unstructured":"He, Y., Tsou, P. S., Khanna, D. & Sawalha, A. H. Methyl-CpG-binding protein 2 mediates antifibrotic effects in scleroderma fibroblasts. Ann. Rheum. Dis. 77, 1208\u20131218 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"99_CR77","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S0002-9440(10)64092-8","volume":"158","author":"CB Keerthisingam","year":"2001","unstructured":"Keerthisingam, C. B. et al. Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-\u03b2 in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. Am. J. Pathol. 158, 1411\u20131422 (2001).","journal-title":"Am. J. Pathol."},{"key":"99_CR78","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1042\/CS20150697","volume":"130","author":"IC Evans","year":"2016","unstructured":"Evans, I. C. et al. Epigenetic regulation of cyclooxygenase-2 by methylation of C8orf4 in pulmonary fibrosis. Clin. Sci. (Lond.) 130, 575\u2013586 (2016).","journal-title":"Clin. Sci. (Lond.)"},{"key":"99_CR79","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.4049\/jimmunol.0900956","volume":"183","author":"J Kim","year":"2009","unstructured":"Kim, J. et al. TC1(C8orf4) is a novel endothelial inflammatory regulator enhancing NF-\u03baB activity. J. Immunol. 183, 3996\u20134002 (2009).","journal-title":"J. Immunol."},{"key":"99_CR80","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12929-015-0142-2","volume":"22","author":"P Matatiele","year":"2015","unstructured":"Matatiele, P., Tikly, M., Tarr, G. & Gulumian, M. DNA methylation similarities in genes of black South Africans with systemic lupus erythematosus and systemic sclerosis. J. Biomed. Sci. 22, 34 (2015).","journal-title":"J. Biomed. Sci."},{"key":"99_CR81","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.jid.2017.12.003","volume":"138","author":"W Ding","year":"2018","unstructured":"Ding, W. et al. Genome-wide DNA methylation analysis in systemic sclerosis reveals hypomethylation of IFN-associated genes in CD4(+) and CD8(+) T cells. J. Invest. Dermatol. 138, 1069\u20131077 (2018).","journal-title":"J. Invest. Dermatol."},{"key":"99_CR82","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.4049\/jimmunol.0901778","volume":"185","author":"A Yoshizaki","year":"2010","unstructured":"Yoshizaki, A. et al. Cell adhesion molecules regulate fibrotic process via Th1\/Th2\/Th17 cell balance in a bleomycin-induced scleroderma model. J. Immunol. 185, 2502\u20132515 (2010).","journal-title":"J. Immunol."},{"key":"99_CR83","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1868-7083-6-25","volume":"6","author":"Y Wang","year":"2014","unstructured":"Wang, Y. et al. Hypomethylation and overexpression of ITGAL (CD11a) in CD4(+) T cells in systemic sclerosis. Clin. Epigenet. 6, 25 (2014).","journal-title":"Clin. Epigenet."},{"key":"99_CR84","doi-asserted-by":"crossref","first-page":"48938","DOI":"10.18632\/oncotarget.16894","volume":"8","author":"H Yin","year":"2017","unstructured":"Yin, H. et al. Histone demethylase JMJD3 regulates CD11a expression through changes in histone H3K27 tri-methylation levels in CD4+ T cells of patients with systemic lupus erythematosus. Oncotarget 8, 48938\u201348947 (2017).","journal-title":"Oncotarget"},{"key":"99_CR85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003678","volume":"9","author":"DM Absher","year":"2013","unstructured":"Absher, D. M. et al. Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T cell populations. PLoS Genet. 9, e1003678 (2013).","journal-title":"PLoS Genet."},{"key":"99_CR86","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/annrheumdis-2011-200275","volume":"71","author":"FD Carmona","year":"2012","unstructured":"Carmona, F. D. et al. Novel identification of the IRF7 region as an anticentromere autoantibody propensity locus in systemic sclerosis. Ann. Rheum. Dis. 71, 114\u2013119 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"99_CR87","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1111\/1756-185X.13175","volume":"20","author":"R Rezaei","year":"2017","unstructured":"Rezaei, R. et al. IRF7 gene expression profile and methylation of its promoter region in patients with systemic sclerosis. Int. J. Rheum. Dis. 20, 1551\u20131561 (2017).","journal-title":"Int. J. Rheum. Dis."},{"key":"99_CR88","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjd.12913","volume":"171","author":"YY Wang","year":"2014","unstructured":"Wang, Y. Y. et al. DNA hypermethylation of the forkhead box protein 3 (FOXP3) promoter in CD4+ T cells of patients with systemic sclerosis. Br. J. Dermatol. 171, 39\u201347 (2014).","journal-title":"Br. J. Dermatol."},{"key":"99_CR89","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000450949","volume":"171","author":"G Almanzar","year":"2016","unstructured":"Almanzar, G. et al. Disease manifestation and inflammatory activity as modulators of Th17\/Treg balance and RORC\/FoxP3 methylation in systemic sclerosis. Int. Arch. Allergy Immunol. 171, 141\u2013154 (2016).","journal-title":"Int. Arch. Allergy Immunol."},{"key":"99_CR90","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1002\/art.39828","volume":"68","author":"PS Tsou","year":"2016","unstructured":"Tsou, P. S. et al. Histone deacetylase 5 is overexpressed in scleroderma endothelial cells and impairs angiogenesis via repression of proangiogenic factors. Arthritis Rheumatol. 68, 2975\u20132985 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"99_CR91","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.21948","volume":"54","author":"Y Wang","year":"2006","unstructured":"Wang, Y., Fan, P. S. & Kahaleh, B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum. 54, 2271\u20132279 (2006).","journal-title":"Arthritis Rheum."},{"key":"99_CR92","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1165\/rcmb.2016-0192OC","volume":"58","author":"H Chu","year":"2018","unstructured":"Chu, H. et al. Sirtuin1 protects against systemic sclerosis-related pulmonary fibrosis by decreasing proinflammatory and profibrotic processes. Am. J. Respir. Cell. Mol. Biol. 58, 28\u201339 (2018).","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"99_CR93","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/annrheumdis-2014-205740","volume":"75","author":"P Zerr","year":"2016","unstructured":"Zerr, P. et al. Sirt1 regulates canonical TGF-\u03b2 signalling to control fibroblast activation and tissue fibrosis. Ann. Rheum. Dis. 75, 226\u2013233 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"99_CR94","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/art.39061","volume":"67","author":"J Wei","year":"2015","unstructured":"Wei, J. et al. The histone deacetylase sirtuin 1 is reduced in systemic sclerosis and abrogates fibrotic responses by targeting transforming growth factor \u03b2 signaling. Arthritis Rheumatol. 67, 1323\u20131334 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"99_CR95","doi-asserted-by":"crossref","first-page":"L945","DOI":"10.1152\/ajplung.00473.2016","volume":"312","author":"AE Wyman","year":"2017","unstructured":"Wyman, A. E. et al. Sirtuin 7 is decreased in pulmonary fibrosis and regulates the fibrotic phenotype of lung fibroblasts. Am. J. Physiol. Lung Cell. Mol. Physiol. 312, L945\u2013L958 (2017).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"99_CR96","first-page":"595","volume":"72","author":"ML Sosulski","year":"2017","unstructured":"Sosulski, M. L., Gongora, R., Feghali-Bostwick, C., Lasky, J. A. & Sanchez, C. G. Sirtuin 3 deregulation promotes pulmonary fibrosis. J. Gerontol. A Biol. Sci. Med. Sci. 72, 595\u2013602 (2017).","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"99_CR97","doi-asserted-by":"crossref","first-page":"69321","DOI":"10.18632\/oncotarget.12504","volume":"7","author":"K Akamata","year":"2016","unstructured":"Akamata, K. et al. SIRT3 is attenuated in systemic sclerosis skin and lungs, and its pharmacologic activation mitigates organ fibrosis. Oncotarget 7, 69321\u201369336 (2016).","journal-title":"Oncotarget"},{"key":"99_CR98","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jdermsci.2017.04.013","volume":"87","author":"X Zhu","year":"2017","unstructured":"Zhu, X. et al. SIRT1 ameliorates systemic sclerosis by targeting the mTOR pathway. J. Dermatol. Sci. 87, 149\u2013158 (2017).","journal-title":"J. Dermatol. Sci."},{"key":"99_CR99","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.clim.2015.03.006","volume":"161","author":"Q Wang","year":"2015","unstructured":"Wang, Q. et al. Overexpression of JMJD3 may contribute to demethylation of H3K27me3 in CD4+ T cells from patients with systemic sclerosis. Clin. Immunol. 161, 396\u2013399 (2015).","journal-title":"Clin. Immunol."},{"key":"99_CR100","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/annrheumdis-2017-211501","volume":"77","author":"C Bergmann","year":"2018","unstructured":"Bergmann, C. et al. The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis. Ann. Rheum. Dis. 77, 150\u2013158 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"99_CR101","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.bbagrm.2015.07.013","volume":"1849","author":"Z Fan","year":"2015","unstructured":"Fan, Z. et al. MKL1 is an epigenetic modulator of TGF-\u03b2 induced fibrogenesis. Biochim. Biophys. Acta 1849, 1219\u20131228 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"99_CR102","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/art.40163","volume":"69","author":"M Rossato","year":"2017","unstructured":"Rossato, M. et al. Association of microRNA-618 expression with altered frequency and activation of plasmacytoid dendritic cells in patients with systemic sclerosis. Arthritis Rheumatol. 69, 1891\u20131902 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"99_CR103","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/eci.12776","volume":"47","author":"M Ciechomska","year":"2017","unstructured":"Ciechomska, M. et al. The role of microRNA-5196 in the pathogenesis of systemic sclerosis. Eur. J. Clin. Invest. 47, 555\u2013564 (2017).","journal-title":"Eur. J. Clin. Invest."},{"key":"99_CR104","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115596","volume":"9","author":"M Ciechomska","year":"2014","unstructured":"Ciechomska, M., O\u2019Reilly, S., Suwara, M., Bogunia-Kubik, K. & van Laar, J. M. MiR-29a reduces TIMP-1 production by dermal fibroblasts via targeting TGF-\u03b2 activated kinase 1 binding protein 1, implications for systemic sclerosis. PLoS ONE 9, e115596 (2014).","journal-title":"PLoS ONE"},{"key":"99_CR105","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/08916934.2015.1030616","volume":"48","author":"S Jafarinejad-Farsangi","year":"2015","unstructured":"Jafarinejad-Farsangi, S. et al. MicroRNA-29a induces apoptosis via increasing the Bax:Bcl-2 ratio in dermal fibroblasts of patients with systemic sclerosis. Autoimmunity 48, 369\u2013378 (2015).","journal-title":"Autoimmunity"},{"key":"99_CR106","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/ijd.13308","volume":"55","author":"S Jafarinejad-Farsangi","year":"2016","unstructured":"Jafarinejad-Farsangi, S. et al. Inhibition of microRNA-21 induces apoptosis in dermal fibroblasts of patients with systemic sclerosis. Int. J. Dermatol. 55, 1259\u20131267 (2016).","journal-title":"Int. J. Dermatol."},{"key":"99_CR107","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.biopha.2016.12.080","volume":"87","author":"B Zhou","year":"2017","unstructured":"Zhou, B. et al. MicroRNA-202-3p regulates scleroderma fibrosis by targeting matrix metalloproteinase 1. Biomed. Pharmacother. 87, 412\u2013418 (2017).","journal-title":"Biomed. Pharmacother."},{"key":"99_CR108","volume":"6","author":"Q Yan","year":"2016","unstructured":"Yan, Q., Chen, J., Li, W., Bao, C. & Fu, Q. Targeting miR-155 to treat experimental scleroderma. Sci. Rep. 6, 20314 (2016).","journal-title":"Sci. Rep."},{"key":"99_CR109","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13075-016-1054-6","volume":"18","author":"RB Christmann","year":"2016","unstructured":"Christmann, R. B. et al. MiR-155 in the progression of lung fibrosis in systemic sclerosis. Arthritis Res. Ther. 18, 155 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"99_CR110","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13075-017-1331-z","volume":"19","author":"CM Artlett","year":"2017","unstructured":"Artlett, C. M., Sassi-Gaha, S., Hope, J. L., Feghali-Bostwick, C. A. & Katsikis, P. D. Mir-155 is overexpressed in systemic sclerosis fibroblasts and is required for NLRP3 inflammasome-mediated collagen synthesis during fibrosis. Arthritis Res. Ther. 19, 144 (2017).","journal-title":"Arthritis Res. Ther."},{"key":"99_CR111","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1002\/art.30568","volume":"63","author":"CM Artlett","year":"2011","unstructured":"Artlett, C. M. et al. The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis. Arthritis Rheum. 63, 3563\u20133574 (2011).","journal-title":"Arthritis Rheum."},{"key":"99_CR112","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/annrheumdis-2014-205326","volume":"75","author":"N Iwamoto","year":"2016","unstructured":"Iwamoto, N. et al. Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression. Ann. Rheum. Dis. 75, 303\u2013310 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"99_CR113","doi-asserted-by":"crossref","first-page":"850","DOI":"10.4161\/rna.20378","volume":"9","author":"M Weiland","year":"2012","unstructured":"Weiland, M., Gao, X. H., Zhou, L. & Mi, Q. S. Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases. RNA Biol. 9, 850\u2013859 (2012).","journal-title":"RNA Biol."},{"key":"99_CR114","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3899\/jrheum.140502","volume":"42","author":"SO Steen","year":"2015","unstructured":"Steen, S. O. et al. The circulating cell-free microRNA profile in systemic sclerosis is distinct from both healthy controls and systemic lupus erythematosus. J. Rheumatol. 42, 214\u2013221 (2015).","journal-title":"J. Rheumatol."},{"key":"99_CR115","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1093\/rheumatology\/kev234","volume":"54","author":"DM Wuttge","year":"2015","unstructured":"Wuttge, D. M. et al. Specific autoantibody profiles and disease subgroups correlate with circulating micro-RNA in systemic sclerosis. Rheumatol. 54, 2100\u20132107 (2015).","journal-title":"Rheumatol."},{"key":"99_CR116","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaut.2017.12.015","volume":"89","author":"E Chouri","year":"2018","unstructured":"Chouri, E. et al. Serum microRNA screening and functional studies reveal miR-483-5p as a potential driver of fibrosis in systemic sclerosis. J. Autoimmun. 89, 162\u2013170 (2018).","journal-title":"J. Autoimmun"},{"key":"99_CR117","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jdermsci.2016.06.013","volume":"84","author":"K Nakamura","year":"2016","unstructured":"Nakamura, K. et al. Altered expression of CD63 and exosomes in scleroderma dermal fibroblasts. J. Dermatol. Sci. 84, 30\u201339 (2016).","journal-title":"J. Dermatol. Sci."},{"issue":"Suppl. 106","key":"99_CR118","first-page":"21","volume":"35","author":"PJ Wermuth","year":"2017","unstructured":"Wermuth, P. J., Piera-Velazquez, S. & Jimenez, S. A. Exosomes isolated from serum of systemic sclerosis patients display alterations in their content of profibrotic and antifibrotic microRNA and induce a profibrotic phenotype in cultured normal dermal fibroblasts. Clin. Exp. Rheumatol. 35 (Suppl. 106), 21\u201330 (2017).","journal-title":"Clin. Exp. Rheumatol."},{"key":"99_CR119","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jid.2017.09.053","volume":"138","author":"TC Messemaker","year":"2018","unstructured":"Messemaker, T. C. et al. Antisense long non-coding RNAs are deregulated in skin tissue of patients with systemic sclerosis. J. Invest. Dermatol. 138, 826\u2013835 (2018).","journal-title":"J. Invest. Dermatol."},{"key":"99_CR120","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/exd.12900","volume":"25","author":"Z Wang","year":"2016","unstructured":"Wang, Z. et al. Long non-coding RNA TSIX is upregulated in scleroderma dermal fibroblasts and controls collagen mRNA stabilization. Exp. Dermatol. 25, 131\u2013136 (2016).","journal-title":"Exp. Dermatol."},{"key":"99_CR121","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2217\/epi-2016-0136","volume":"9","author":"C Angiolilli","year":"2017","unstructured":"Angiolilli, C., Baeten, D. L., Radstake, T. R. & Reedquist, K. A. The acetyl code in rheumatoid arthritis and other rheumatic diseases. Epigenomics 9, 447\u2013461 (2017).","journal-title":"Epigenomics"},{"key":"99_CR122","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key071","author":"S O\u2019Reilly","year":"2018","unstructured":"O\u2019Reilly, S. Epigenetic modulation as a therapy in systemic sclerosis. Rheumatol. https:\/\/doi.org\/10.1093\/rheumatology\/key071 (2018).","journal-title":"Rheumatol."},{"key":"99_CR123","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000147","volume":"3","author":"FM Strickland","year":"2016","unstructured":"Strickland, F. M. et al. Characterisation of an epigenetically altered CD4(+) CD28(+) KIR(+) T cell subset in autoimmune rheumatic diseases by multiparameter flow cytometry. Lupus Sci. Med. 3, e000147 (2016).","journal-title":"Lupus Sci. Med."},{"key":"99_CR124","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/0198-8859(86)90304-6","volume":"17","author":"B Richardson","year":"1986","unstructured":"Richardson, B. Effect of an inhibitor of DNA methylation on T cells. II. 5-Azacytidine induces self-reactivity in antigen-specific T4+ cells. Hum. Immunol. 17, 456\u2013470 (1986).","journal-title":"Hum. Immunol."},{"key":"99_CR125","doi-asserted-by":"crossref","first-page":"ra84","DOI":"10.1126\/scisignal.2004592","volume":"7","author":"S Svegliati","year":"2014","unstructured":"Svegliati, S. et al. Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis. Sci. Signal 7, ra84 (2014).","journal-title":"Sci. Signal"},{"key":"99_CR126","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1002\/art.22759","volume":"56","author":"LC Huber","year":"2007","unstructured":"Huber, L. C. et al. Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum. 56, 2755\u20132764 (2007).","journal-title":"Arthritis Rheum."},{"key":"99_CR127","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3109\/01902148.2015.1060275","volume":"41","author":"C Ota","year":"2015","unstructured":"Ota, C. et al. Histone deacetylase inhibitor restores surfactant protein-C expression in alveolar-epithelial type II cells and attenuates bleomycin-induced pulmonary fibrosis in vivo. Exp. Lung Res. 41, 422\u2013434 (2015).","journal-title":"Exp. Lung Res."},{"key":"99_CR128","first-page":"696","volume":"7","author":"L Hu","year":"2016","unstructured":"Hu, L. et al. Epigenetic regulation of interleukin 6 by histone acetylation in macrophages and its role in paraquat-induced pulmonary fibrosis. Front. Immunol. 7, 696 (2016).","journal-title":"Front. Immunol."},{"key":"99_CR129","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/jid.2012.479","volume":"133","author":"AK Ghosh","year":"2013","unstructured":"Ghosh, A. K. et al. p300 is elevated in systemic sclerosis and its expression is positively regulated by TGF-\u03b2: epigenetic feed-forward amplification of fibrosis. J. Invest. Dermatol. 133, 1302\u20131310 (2013).","journal-title":"J. Invest. Dermatol."},{"key":"99_CR130","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/gerona\/glr062","volume":"67","author":"JM Smoliga","year":"2012","unstructured":"Smoliga, J. M., Vang, O. & Baur, J. A. Challenges of translating basic research into therapeutics: resveratrol as an example. J. Gerontol. A Biol. Sci. Med. Sci. 67, 158\u2013167 (2012).","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"99_CR131","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.12915","volume":"4","author":"X Xiao","year":"2016","unstructured":"Xiao, X. et al. EZH2 enhances the differentiation of fibroblasts into myofibroblasts in idiopathic pulmonary fibrosis. Physiol. Rep. 4, e12915 (2016).","journal-title":"Physiol. Rep."},{"key":"99_CR132","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ymthe.2016.10.004","volume":"25","author":"M Zeybel","year":"2017","unstructured":"Zeybel, M. et al. A proof-of-concept for epigenetic therapy of tissue fibrosis: inhibition of liver fibrosis progression by 3-deazaneplanocin A. Mol. Ther. 25, 218\u2013231 (2017).","journal-title":"Mol. Ther."},{"key":"99_CR133","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/art.39602","volume":"68","author":"M Ciechomska","year":"2016","unstructured":"Ciechomska, M. et al. Histone demethylation and toll-like receptor 8-dependent cross-talk in monocytes promotes transdifferentiation of fibroblasts in systemic sclerosis via Fra-2. Arthritis Rheumatol. 68, 1493\u20131504 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"99_CR134","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/annrheumdis-2012-201615","volume":"72","author":"M Kramer","year":"2013","unstructured":"Kramer, M. et al. Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. Ann. Rheum. Dis. 72, 614\u2013620 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"99_CR135","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","volume":"54","author":"J Shi","year":"2014","unstructured":"Shi, J. & Vakoc, C. R. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol. Cell 54, 728\u2013736 (2014).","journal-title":"Mol. Cell"},{"key":"99_CR136","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ajpath.2013.04.020","volume":"183","author":"X Tang","year":"2013","unstructured":"Tang, X. et al. Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosis. Am. J. Pathol. 183, 470\u2013479 (2013).","journal-title":"Am. J. Pathol."},{"key":"99_CR137","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13075-016-0929-x","volume":"18","author":"S O\u2019Reilly","year":"2016","unstructured":"O\u2019Reilly, S. MicroRNAs in fibrosis: opportunities and challenges. Arthritis Res. Ther. 18, 11 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"99_CR138","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/rheumatology\/ket254","volume":"52","author":"S Tanaka","year":"2013","unstructured":"Tanaka, S. et al. Alteration of circulating miRNAs in SSc: miR-30b regulates the expression of PDGF receptor beta. Rheumatol. 52, 1963\u20131972 (2013).","journal-title":"Rheumatol."},{"key":"99_CR139","first-page":"A9","volume":"24","author":"CL Gallant-Behm","year":"2016","unstructured":"Gallant-Behm, C. L. et al. Regulation of ECM production and fibrosis by MRG-201, a mimic of microRNA miR-29. Wound Repair Regener. 24, A9 (2016).","journal-title":"Wound Repair Regener."},{"key":"99_CR140","doi-asserted-by":"crossref","first-page":"B4","DOI":"10.1016\/j.jid.2017.07.022","volume":"137","author":"CL Gallant-Behm","year":"2017","unstructured":"Gallant-Behm, C. L. et al. Pharmacodynamic activity of a microRNA-29b mimic (MRG-201) in human skin incisions. J. Investigative Dermatol. 137, B4 (2017).","journal-title":"J. Investigative Dermatol."},{"key":"99_CR141","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00438-016-1264-2","volume":"292","author":"F Kader","year":"2017","unstructured":"Kader, F. & Ghai, M. DNA methylation-based variation between human populations. Mol. Genet. Genom. 292, 5\u201335 (2017).","journal-title":"Mol. Genet. Genom."},{"key":"99_CR142","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4103\/2229-3485.179431","volume":"7","author":"AF Christopher","year":"2016","unstructured":"Christopher, A. F. et al. MicroRNA therapeutics: discovering novel targets and developing specific therapy. Perspect. Clin. Res. 7, 68\u201374 (2016).","journal-title":"Perspect. Clin. Res."},{"key":"99_CR143","doi-asserted-by":"crossref","first-page":"225re1","DOI":"10.1126\/scitranslmed.3008089","volume":"6","author":"J Guinea-Viniegra","year":"2014","unstructured":"Guinea-Viniegra, J. et al. Targeting miR-21 to treat psoriasis. Sci. Transl Med. 6, 225re1 (2014).","journal-title":"Sci. Transl Med."},{"key":"99_CR144","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/13543776.2016.1209488","volume":"26","author":"P Xu","year":"2016","unstructured":"Xu, P., Hu, G., Luo, C. & Liang, Z. DNA methyltransferase inhibitors: an updated patent review (2012\u20132015). Expert Opin. Ther. Pat. 26, 1017\u20131030 (2016).","journal-title":"Expert Opin. Ther. Pat."},{"key":"99_CR145","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/art.30238","volume":"63","author":"J Vojinovic","year":"2011","unstructured":"Vojinovic, J. et al. Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 63, 1452\u20131458 (2011).","journal-title":"Arthritis Rheum."},{"key":"99_CR146","first-page":"783","volume":"371","author":"TE King Jr.","year":"2014","unstructured":"King, T. E. Jr., Noble, P. W. & Bradford, W. Z. Treatments for idiopathic pulmonary fibrosis. N. Engl. J. Med. 371, 783\u2013784 (2014).","journal-title":"N. Engl. J. Med."},{"key":"99_CR147","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"381","author":"P Marcellin","year":"2013","unstructured":"Marcellin, P. et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381, 468\u2013475 (2013).","journal-title":"Lancet"},{"key":"99_CR148","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jhep.2013.05.007","volume":"59","author":"YF Liaw","year":"2013","unstructured":"Liaw, Y. F. Reversal of cirrhosis: an achievable goal of hepatitis B antiviral therapy. J. Hepatol. 59, 880\u2013881 (2013).","journal-title":"J. Hepatol."},{"key":"99_CR149","doi-asserted-by":"crossref","first-page":"C216","DOI":"10.1152\/ajpcell.00328.2012","volume":"304","author":"M Zeisberg","year":"2013","unstructured":"Zeisberg, M. & Kalluri, R. Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. Am. J. Physiol. Cell Physiol. 304, C216\u2013C225 (2013).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"99_CR150","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.4238\/2014.June.16.6","volume":"13","author":"L Tang","year":"2014","unstructured":"Tang, L., Chen, B., Ma, B. & Nie, S. Association between IRF5 polymorphisms and autoimmune diseases: a meta-analysis. Genet. Mol. Res. 13, 4473\u20134485 (2014).","journal-title":"Genet. Mol. Res."},{"key":"99_CR151","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/039463201402700420","volume":"27","author":"J Wang","year":"2014","unstructured":"Wang, J. et al. Association of the IRF5 SNP rs2004640 with systemic sclerosis in Han Chinese. Int. J. Immunopathol. Pharmacol. 27, 635\u2013638 (2014).","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"99_CR152","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00296-017-3722-5","volume":"37","author":"W Zhao","year":"2017","unstructured":"Zhao, W. et al. The status of pulmonary fibrosis in systemic sclerosis is associated with IRF5, STAT4, IRAK1, and CTGF polymorphisms. Rheumatol. Int. 37, 1303\u20131310 (2017).","journal-title":"Rheumatol. Int."},{"key":"99_CR153","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3109\/14397595.2014.1001311","volume":"25","author":"H Luo","year":"2015","unstructured":"Luo, H., Zhu, H., Zhou, B., Xiao, X. & Zuo, X. MicroRNA-130b regulates scleroderma fibrosis by targeting peroxisome proliferator-activated receptor gamma. Mod. Rheumatol. 25, 595\u2013602 (2015).","journal-title":"Mod. Rheumatol."},{"key":"99_CR154","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/rheumatology\/kew336","volume":"56","author":"W Nakayama","year":"2017","unstructured":"Nakayama, W. et al. Dysregulated interleukin-23 signalling contributes to the increased collagen production in scleroderma fibroblasts via balancing microRNA expression. Rheumatol. 56, 145\u2013155 (2017).","journal-title":"Rheumatol."},{"key":"99_CR155","doi-asserted-by":"crossref","first-page":"C616","DOI":"10.1152\/ajpcell.00086.2015","volume":"309","author":"WA Neveu","year":"2015","unstructured":"Neveu, W. A., Mills, S. T., Staitieh, B. S. & Sueblinvong, V. TGF-\u03b21 epigenetically modifies Thy-1 expression in primary lung fibroblasts. Am. J. Physiol. Cell Physiol. 309, C616\u2013C626 (2015).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"99_CR156","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nm.3777","volume":"21","author":"K Palumbo-Zerr","year":"2015","unstructured":"Palumbo-Zerr, K. et al. Orphan nuclear receptor NR4A1 regulates transforming growth factor-\u03b2 signaling and fibrosis. Nat. Med. 21, 150\u2013158 (2015).","journal-title":"Nat. Med."},{"key":"99_CR157","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jdcr.2014.11.004","volume":"1","author":"JR Urban","year":"2015","unstructured":"Urban, J. R. & King, B. Divalproex sodium: a potential therapy for scleroderma digital ulcers. JAAD Case Rep. 1, 44\u201345 (2015).","journal-title":"JAAD Case Rep."},{"key":"99_CR158","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.jid.2018.01.006","volume":"138","author":"M Hinchcliff","year":"2018","unstructured":"Hinchcliff, M. et al. Mycophenolate mofetil treatment of systemic sclerosis reduces myeloid cell numbers and attenuates the inflammatory gene signature in skin. J. Invest. Dermatol. 138, 1301\u20131310 (2018).","journal-title":"J. Invest. Dermatol."},{"key":"99_CR159","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/acr.23282","volume":"70","author":"R Namas","year":"2018","unstructured":"Namas, R. et al. Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials. Arthritis Care Res. (Hoboken) 70, 439\u2013444 (2018).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"99_CR160","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.40114","volume":"69","author":"ER Volkmann","year":"2017","unstructured":"Volkmann, E. R. et al. Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II. Arthritis Rheumatol. 69, 1451\u20131460 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"99_CR161","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin, D. P. et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir. Med. 4, 708\u2013719 (2016).","journal-title":"Lancet Respir. Med."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41584-018-0099-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-018-0099-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-018-0099-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:21:39Z","timestamp":1775244099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-018-0099-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,10]]},"references-count":161,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["99"],"URL":"https:\/\/doi.org\/10.1038\/s41584-018-0099-0","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,10]]},"assertion":[{"value":"10 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}